Amylyx Pharmaceuticals (NASDAQ:AMLX) Insider Sells $309,538.56 in Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Gina Mazzariello sold 9,536 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $32.46, for a total transaction of $309,538.56. Following the transaction, the insider owned 190,838 shares in the company, valued at approximately $6,194,601.48. The trade was a 4.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Gina Mazzariello also recently made the following trade(s):

• On Thursday, July 9th, Gina Mazzariello sold 15,000 shares of Amylyx Pharmaceuticals stock. The shares were sold at an average price of $18.32, for a total transaction of $274,800.00.

Amylyx Pharmaceuticals Stock Performance

Amylyx Pharmaceuticals stock traded up $2.02 during trading on Monday, reaching $33.64. The company had a trading volume of 1,816,910 shares, compared to its average volume of 1,682,389. Amylyx Pharmaceuticals, Inc. has a 12-month low of $10.83 and a 12-month high of $41.14. The stock’s 50 day moving average price is $25.69 and its two-hundred day moving average price is $18.87. The firm has a market capitalization of $3.75 billion, a price-to-earnings ratio of -23.52 and a beta of -0.13.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). As a group, research analysts expect that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current year.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in shares of Amylyx Pharmaceuticals in the second quarter worth about $158,534,000. Jupiter Topco LLC acquired a new position in Amylyx Pharmaceuticals during the 2nd quarter worth approximately $94,014,000. Janus Henderson Group PLC boosted its holdings in Amylyx Pharmaceuticals by 11.6% in the 1st quarter. Janus Henderson Group PLC now owns 4,986,073 shares of the company’s stock worth $69,257,000 after acquiring an additional 520,201 shares during the period. Commodore Capital LP boosted its holdings in Amylyx Pharmaceuticals by 38.6% in the 4th quarter. Commodore Capital LP now owns 5,650,000 shares of the company’s stock worth $68,252,000 after acquiring an additional 1,574,522 shares during the period. Finally, California State Teachers Retirement System grew its position in Amylyx Pharmaceuticals by 2,106.9% in the second quarter. California State Teachers Retirement System now owns 1,434,501 shares of the company’s stock valued at $25,764,000 after acquiring an additional 1,369,499 shares in the last quarter. Institutional investors and hedge funds own 95.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on AMLX shares. Citigroup increased their target price on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Mizuho upped their price target on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Wednesday, August 5th. Guggenheim lifted their price objective on Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the company a “buy” rating in a research note on Thursday, August 27th. Finally, Wolfe Research upgraded Amylyx Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 17th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $36.50.

Amylyx Pharmaceuticals Company Profile